Presentations

• March 17, 2023
  

  The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs

  Appropriate endpoint selection for rare disease trials is challenging. The Rare Disease Clinical Outcome Assessment (COA) Consortium’s aim is the creation of a resource of publicly available COAs deemed fit-for-purpose as trial endpoint measures. You can view the full presentation here.
• January 5, 2023
  

  Using Real World Data from CURE ID to Identify Drug Repurposing Opportunities in Mycology: Impact of Climate Change

• November 30, 2022
  

  Drug Repurposing Roadmap that Optimizes Patient Impact through Collaboration

• November 9, 2022
  

  Innovative Use of Healthcare Data, ERN Data Management Strategy Multistakeholder Workshop

• October 12, 2022
  

  Making Sense of Monkeypox